Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Maria Vassilakopoulou, Kurt A. Schalper, Helena Linardou, Jennifer Bordeaux, George Fountzilas, David L. Rimm, Huan Cheng, Nicholas Pavlidis, Veronique Neumeister, Dimosthenis Skarlos, Dimitrios G. Pectasides, Mattheos Bobos, Angelos Koutras, Amanda Psyrri, Vassiliki Kotoula, Evangelia Razis
Publikováno v:
Journal of Clinical Oncology. 30:573-573
573 Background: Trastuzumab therapy is currently selected based on assessment of HER2 by either immunohistochemistry (IHC) for protein over-expression or fluorescence in situ hybridization (FISH) to detect gene amplification. We sought to determine t
Autor:
K. Koch, R. C. Coombes, M. Lau, Azeem Saleem, S. C. Carme, Mickael Huiban, Graham E. Searle, J. A. Reise, P. Burgess, A. Das-Gupta
Publikováno v:
Journal of Clinical Oncology. 29:TPS107-TPS107
TPS107 Background: Patients with HER2+ breast cancer tend to develop visceral metastases. Several anti-cancer agents including trastuzumab are not believed to readily cross the blood-brain barrier (BBB); hence, central nervous system (CNS) disease pr
Autor:
R. Duchnowska, Wei Huang, Jacek Jassem, Barbara Szostakiewicz, Jodi Weidler, B. Arlukowicz-Czartoryska, Michael Bates, T Jankowski, Mojgan Haddad, Piotr J. Wysocki
Publikováno v:
Journal of Clinical Oncology. 28:1030-1030
1030 Background: Breast cancer is estimated to be the second most frequent cause of BM; however biological basis of this phenomenon is not well established. Pts with HER2-overexpressing breast cancer are at greater risk for BM. This study sought to i
Autor:
Michael F. Press, David Cameron, Charles E. Geyer, Maria Koehler, Anne-Marie Martin, M. Arbushites, B. Newstat, Richard S. Finn, A. Di Leo, Robert C. Gagnon
Publikováno v:
Journal of Clinical Oncology. 26:1007-1007
1007 Background: Lapatinib (L), an oral small molecule tyrosine kinase inhibitor of EGFR and HER2, is approved in combination with capecitabine for the treatment of women with HER2+ metastatic breast cancer (MBC). The optimal method to select patient
Publikováno v:
Journal of Clinical Oncology. 26:1017-1017
1017 Background: It has been hypothesized that women with HER2-negative MBC respond to HER2-targeted drugs if the circulating baseline HER2 ECD is >16 ng/ml. Lapatinib, an oral, dual inhibitor of HER2 and EGFR, is effective in women with HER2+ MBC. W
Autor:
Michael F. Press, A. Di Leo, Robert B. Livingston, Maria Koehler, M. Arbushites, L. S. Williams, Leona Downey
Publikováno v:
Journal of Clinical Oncology. 26:1006-1006
1006 Background: Patients with polysomy of Chr-17 have been suggested as a FISH-negative subpopulation that might benefit from HER2-directed therapy, due to an increase in HER2 gene expression without HER2 specific amplification. A recent phase III c
Autor:
W.L. Kuo, L. S. Williams, Maria Koehler, M. Arbushites, Nicholas J. Wang, Catherine E. Ellis, D. Das, Joe W. Gray, Michael F. Press, A. Di Leo
Publikováno v:
Journal of Clinical Oncology. 26:1043-1043
1043 Background: Identification of molecular predictors of response is an important aspect of efforts to individualize cancer treatment. Responses to lapatinib (L), an oral, dual inhibitor of HER2 and EGFR approved in combination with capecitabine fo
Autor:
Seigo Nakamura, Wei Huang, Jeff Sperinde, Michael Bates, Noriyuki Masuda, Shinji Ohno, H. Iwata, Kenjiro Aogi, Masakazu Toi, Shigetoyo Saji
Publikováno v:
Journal of Clinical Oncology. 25:1025-1025
1025 Background: Women with metastatic breast cancer (MBC) that overexpress HER2 experience improved overall survival (OS) when treated with trastuzumab. Immunohistochemistry (IHC) for HER2 protein expression and fluorescence in situ hybridization (F
Autor:
N. Xiros, A. Karabelis, V. Kostopoulou, A. Gaglia, C. Valavanis, Michail Nikolaou, D.G. Pectasides, A Bobota, P. Arapantoni, N. Mylonakis
Publikováno v:
Journal of Clinical Oncology. 23:2094-2094
2094 Background: The aim of this prospective study was to evaluate mechanisms of resistance to trastuzumab in patients with MBC. Methods: Sixteen patients with Her2/neu overexpressing tumors (15 were 3+ by immunohistochemistry (IHC) and one 2+ by IHC
Publikováno v:
Journal of Clinical Oncology. 23:681-681
681 Background: Measuring HER2 is required for the selection of metastatic breast cancer (MBC) patients for trastuzumab therapy. Since the guideline was widely accepted that recommended initial tes...